尿激酶治疗以偏瘫为主的急性脑梗塞160例疗效观察  

The Observation on Efficacy of Urokinasum (UK) in the Treatment of Cerebral Infarction With the Inital Ictal Moter Manifestions In 160 Patients

作　　者：吴祖舜[1] 袁佩芳[1] 王小冬[1] 高俊凤[1] 冯美江[1] 

机构地区：[1]南京医科大学第二附属医院神经科,210011

出　　处：《脑与神经疾病杂志》1998年第4期216-218,共3页Journal of Brain and Nervous Diseases

摘　　要：本文报告急性脑梗塞260例,其中160例急性脑梗塞应用尿激酶10万~U+N·S100ml,静脉滴注,q12h×10天;100例应用Svate-Ⅲ 2~U+N·S100ml,静脉滴注一次/日×15天,两组同时应用Ca^(++)拮抗剂,稀释疗法及脑细胞赋形剂治疗。结果尿激酶组基愈率为65%,显效率90.63%,总有效率达96.26%,非常显著优于Svate-Ⅲ的51%、75%及89%。结果提示尿激酶治疗急性脑梗塞在注意出血倾向发生时是安全、有效的。Urokinasum is a dissovle-emloli medicine, which can improve microcirculation. 160 patients with cerebral infarction in acute period treated were observed. Rate of striking effect and total improvement rate were 90. 63% and 96. 26% respectively. Compered with 100 patients controls with Svate- Ⅲ , which rate of striking effect and total improvement rate were 75% and 89% respectively. There were marked differences in striking effect rate and total improvement rate (P<0. 01). The data indicated that effect of this medicine was apparent, safe with little side-effects. UK is suitable for early use.

关 键 词：尿激酶 急性 脑梗塞 Svate-Ⅲ 治疗 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学]